Eli Lilly To Present New Data Across Its Cardiometabolic Portfolio At American Diabetes Association's 86th Scientific Sessions
Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefine oral incretin



























